Nutriband Inc
NTRB
Detailliertes Diagramm anzeigen
7.220USD
-0.040-0.55%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
79.96MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-0.55%
5 Tage
+0.98%
1 Monat
+16.08%
6 Monate
+10.40%
Seit Jahresbeginn
+53.29%
1 Jahr
+28.93%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert: 2025-09-19Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer schwachen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
1
Analysten
Kaufen
Aktuelles Rating
15.000
Kursziel
+106.61%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
performance_growth_period
performance_growth_period_desc%!(EXTRA string=2.14M)
high_profit_growth
high_profit_growth_desc%!(EXTRA string=133.81)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-7.97)
institutional_increasing_position
institutional_increasing_position_desc%!(EXTRA string=8.87M, string=5.23%)
institutional_hold%!(EXTRA string=The Vanguard)
institutional_hold_desc%!(EXTRA string=The Vanguard, string=199.63K)
activity_increase
activity_increase_desc%!(EXTRA string=1.68)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
BörsenkürzelNTRB
UnternehmenNutriband Inc
CEOMr. Serguei Melnik
Websitehttps://nutriband.com/
Verwandte Finanzinstrumente
+1.09%
-0.27%
-0.53%
-0.28%
-0.71%
+0.10%
-0.69%
-10.99%
-0.69%
-0.80%
-0.12%
-0.05%
-0.49%
+1.41%
-0.87%
-2.83%
-0.83%
-0.89%
-1.01%
+0.33%
